TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01956240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching-Asymptomatic subjects
Description: The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching-Subjects with shoulder pain
Description: The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
Study: NCT02517593

Intervention type: GENETIC
Group type: OTHER
Intervention: Polygenic Risk Score
Description: A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40%).
Study: NCT01504386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TAP block
Description: Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
Study: NCT03034759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized insulin sensitivity index (ISind)
Description: The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads.
Study: NCT04793854

Intervention type: OTHER
Intervention: Measure of the Life habits (MHAVIE)
Description: Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,...).

Intervention type: OTHER
Intervention: Measure of the Life habits (MHAVIE)
Description: Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,...).
Study: NCT00218426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone implant
Description: naltrexone implant is 1000 mg naltrexone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Description: oral naltrexone 50 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral placebo naltrexone
Description: oral placebo naltrexone resembles active medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo naltrexone
Description: oral placebo naltrexone resembles active medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo implant
Description: placebo implant resembles active medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo implant
Description: placebo implant resembles active medication
Study: NCT05254613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).
Study: NCT02338492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic Bone Stabilization System
Description: Treatment of impending and actual pathological fractures of the humerus
Study: NCT03677895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
Study: NCT00582062

Intervention type: OTHER
Intervention: washings for experimental marker testing
Description: During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).

Intervention type: OTHER
Intervention: washings for experimental marker testing
Description: During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
Study: NCT02049801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK inhibitor MEK162
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01993862

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same Day Discharge
Description: Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
Study: NCT02470052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OL-BF-001
Description: Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
Study: NCT00155454

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intravitreal long acting gas (10% C3F8)
Description: At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal long acting gas (10% C3F8)
Description: At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
Study: NCT03279302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Solution for injection
Study: NCT03329651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Description: Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2
Study: NCT01035242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: association splitting
Description: Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive remediation
Description: Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
Study: NCT04316663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-Being Intervention
Description: The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
Study: NCT01815112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
Study: NCT04328519

Intervention type: OTHER
Intervention: observation
Description: observation

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT02477774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARISTA
Description: According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
Study: NCT00521274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 5T4
Description: Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
Study: NCT00922558

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Evaluation of postural control
Description: Children will be measured once using a Tetra-aximetric posturography method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of postural control
Description: Children will be measured once using a Tetra-aximetric posturography method
Study: NCT01402180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Study: NCT04158336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 is a study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 is a study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 is a study drug
Study: NCT02979093

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: All women will receive a nasal spray containing oxytocin.
Study: NCT03157895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connecting
Description: Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
Study: NCT01849276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00731523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod (FTY720)
Study: NCT00118508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risedronate (including placebo)
Description: risedronate 35mg weekly
Study: NCT00523406

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy and intravitreal triamcinolone
Description: combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy and intravitreal triamcinolone
Description: combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
Study: NCT02462941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Testing escalating doses of adenosine in pediatric heart transplant patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Description: (non-experimental) standard procedure
Study: NCT04376606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation group
Description: Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
Study: NCT03449316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhaler technique education
Description: Teaching of inhalers use with placebo devices in real training
Study: NCT04568941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vacuum-Assisted Biopsy
Description: Vacuum-Assisted Biopsy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Needle Biopsy
Description: Core Needle Biopsy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intraoperative Excisional Biopsy
Description: Intraoperative Excisional Biopsy
Study: NCT01061203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazax
Description: Treatment with 75.000 SQ-T once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet with no active grass component.
Study: NCT02156050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two sessions of 4 hours Phototherapy treatment
Description: two sessions of 4 hours Phototherapy treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two sessions of 4 hours Phototherapy treatment
Description: two sessions of 4 hours Phototherapy treatment
Study: NCT00869258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, docetaxel, and capecitabine
Description: Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy with gemzar
Description: Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
Study: NCT00636207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dry powder inhaler
Study: NCT00523107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: PG2 500 mg / 500 ml normal saline t.i.w. per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PG2
Description: PG2 500 mg / 500 ml normal saline t.i.w. per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml normal saline t.i.w. per week
Study: NCT01396837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RedDress Wound Care System (RD1)
Description: Weekly application. A blood based wound care treatment
Study: NCT02473419

Intervention type: DRUG
Intervention: Vayarin

Intervention type: DRUG
Intervention: Vayarin

Intervention type: DRUG
Intervention: Placebo

Intervention type: DRUG
Intervention: Placebo